Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring
We discuss all that and more this week on “The Re…
February 4, 202134m 16s
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck CEO Ken Frazier's retirement after three decades at the drug maker, and how the future of Biogen’s Alzheimer’s disease drug got a little more complicated. Then, Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, joins us to weigh in on the bounty of recent Covid-19 vaccine data from Johnson & Johnson, Novavax, and AstraZeneca. Finally, STAT's Casey Ross calls in to discuss his investigation into the FDA's chaotic approach to approving medical products that use artificial intelligence.